Dexamethasone News and Research

RSS

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.

24 Jan 2012

IQWiG study finds considerable added benefit of abiraterone in prostate cancer patients

Abiraterone has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses further during or after therapy with the cytostatic drug docetaxel.

7 Jan 2012

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers from the John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, presented results from 31 major studies of blood-related cancers - leukemia, lymphoma and multiple myeloma -- during the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2011 in San Diego.

23 Dec 2011

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that updated data evaluating continuous treatment with REVLIMID (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology.

14 Dec 2011

Combination of bortezomib and panobinostat shows promise against advanced MM

When the targeted drug bortezomib stops working in patients with advanced multiple myeloma, the patients survive only an average of five months longer. But a phase 2 clinical trial has shown that pairing bortezomib with an experimental drug, panobinostat, may be a promising new treatment for such patients, Dana-Farber Cancer Institute researchers say.

13 Dec 2011

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

A three-drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center.

13 Dec 2011

New findings from Micromet's blinatumomab phase 1 trial on DLBCL

New findings from a phase 1 trial presented yesterday at the 53rd Annual American Society of Hematology (ASH) Annual Meeting demonstrate Micromet's blinatumomab induces durable responses in patients with extensively pre-treated diffuse large B cell lymphoma.

12 Dec 2011

SCRI to present findings of blood cancer trials at 53rd ASH annual meeting

Sarah Cannon Research Institute (SCRI) investigators will present the findings of several important blood cancer trials during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego December 10-13.

12 Dec 2011

New cancer research findings presented at 53rd ASH annual meeting

Researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine presented new research findings in 25 presentations this weekend at the 53rd Annual Meeting of the American Society of Hematology (ASH) at the San Diego Convention Center.

12 Dec 2011

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.

2 Dec 2011

People with recurrent depression, chronic stress have shorter telomeres in WBCs

People with recurrent depressions or those exposed to chronic stress exhibits shorter telomeres in white blood cells. This is shown by a research team at Umeå University in a coming issue of Biological Psychiatry.

9 Nov 2011

JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM

Keryx Biopharmaceuticals, Inc. today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase l/2 Trial" reporting Phase 1 / 2 combination activity of KRX-0401 (perifosine) in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 11, 2011 online edition of the Journal of Clinical Oncology.

14 Oct 2011

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Celgene International Sàrl was notified today that the E.U. Committee for Medicinal Products for Human Use (CHMP), on behalf of the European Medicines Agency (EMA) has concluded an Article 20 review of REVLIMID and issued a positive opinion for the use of REVLIMID in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

23 Sep 2011

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

Acetylon Pharmaceuticals today announced the initiation of patient treatments in a three-part Phase 1-2a clinical trial of ACY-1215, an oral Class II histone deacetylase (HDAC) inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

22 Sep 2011

Short-term glucocorticoid treatment may prevent osteoarthritis after joint injury

Joint injury can result in irreversible damage of cartilage which, despite treatment and surgery, often eventually leads to osteoarthritis (OA) in later life. New research published in BioMed Central's open access journal Arthritis Research & Therapy demonstrates that short term treatment of damaged cartilage with glucocorticoids can reduce long term degenerative changes and may provide hope for prevention of OA after injury.

2 Sep 2011

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.

4 Aug 2011

Fera adds four ointments to ophthalmic product portfolio

Fera Pharmaceuticals announced the launch today of four ophthalmic ointments.

1 Aug 2011

Microencapsulated cell transplant can help treat chronic illnesses more effectively

Chronic illnesses such as Alzheimer's or Parkinson's could be treated more effectively in the future, by means of the transplant of microencapsulated cells. The researcher from the University of the Basque Country (UPV/EHU) Dr Ainhoa Murua has presented a number of proposals for optimising this technique.

21 Jul 2011

CTI announces positive results from Phase I-II pixantrone combination study against INHL

Cell Therapeutics, Inc. announced the publication of results posted in the online journal of Cancer of a Phase I-II study that evaluated the safety and efficacy of pixantrone when used in combination with fludarabine, dexamethasone and rituximab replacing mitoxantrone in the standard FND-R regimen with FPD-R among 28 patients with relapsed or refractory indolent non-Hodgkin's lymphoma.

17 Jun 2011

Dexamethasone News and Research

Takeda receives FDA approval for VELCADE sNDA to treat MM

IQWiG study finds considerable added benefit of abiraterone in prostate cancer patients

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Combination of bortezomib and panobinostat shows promise against advanced MM

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

New findings from Micromet's blinatumomab phase 1 trial on DLBCL

SCRI to present findings of blood cancer trials at 53rd ASH annual meeting

New cancer research findings presented at 53rd ASH annual meeting

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

People with recurrent depression, chronic stress have shorter telomeres in WBCs

JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

Short-term glucocorticoid treatment may prevent osteoarthritis after joint injury

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

Fera adds four ointments to ophthalmic product portfolio

Microencapsulated cell transplant can help treat chronic illnesses more effectively

CTI announces positive results from Phase I-II pixantrone combination study against INHL

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News